Ho-Sam Ahn
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Blood Coagulation and Thrombosis Mechanisms, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Synthesis and Catalytic Reactions, Antiplatelet Therapy and Cardiovascular Diseases, Phosphodiesterase function and regulation
Most-Cited Works
- → Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity(2008)267 cited
- → Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist(2000)139 cited
- → Discovery of Potent Orally Active Thrombin Receptor (Protease Activated Receptor 1) Antagonists as Novel Antithrombotic Agents(2005)123 cited
- → Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity(1997)80 cited
- → Selective displacement of [3H]mepyramine from peripheral vs. central nervous system receptors by loratadine, a non-sedating antihistamine(1986)74 cited
- → Antiplatelet and Antiproliferative Effects of SCH 51866, a Novel Type 1 and Type 5 Phosphodiesterase Inhibitor(1996)63 cited
- → Wiedendiol-A and -B, cholesteryl ester transfer protein inhibitors from the marine sponge Xestospongia wiedenmayeri(1995)61 cited
- → Binding of a Thrombin Receptor Tethered Ligand Analogue to Human Platelet Thrombin Receptor(1997)59 cited
- → Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists(1999)48 cited
- → Topical Ocular Hypotensive Effects of the Novel Angiotensin Converting Enzyme Inhibitor SCH 33861 in Conscious Rabbits(1987)45 cited